This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Insulet fails second attempt at preliminary injunction against Eoflow at UPC Milan

( November 22, 2024, 12:06 GMT | Official Statement) -- MLex Summary: Insulet Corporation has failed in its bid for a preliminary injunction against EOFlow in its patent dispute over insulin delivery devices, following a decision by the Unified Patent Court’s Milan Central Division. The court initially rejected Insulet’s request in July 2024 and reaffirmed its stance in a final order today. The court also rejected Insulet’s auxiliary requests to amend its patent claims, ruling them inadmissible in the context of provisional measures, and ordered the company to bear the litigation costs, valuing the case at 2.5 million euros and setting the recoverable representation cost ceiling at 400,000 euros.Court document attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login